Overview

Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing

Status:
Not yet recruiting

Trial end date:
2023-12-13

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to assess the target occupancy at kappa and mu opioid receptors in the brain after single oral doses of CVL-354 in healthy adult participants.

Phase:

Phase 1

Details

Lead Sponsor:

Cerevel Therapeutics, LLC

Treatments:

Carfentanil